ESR1 mutations shape the clonal dynamics, genetic diversity and cellular states of acquired resistance to CDK4/6 inhibitors
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 57 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 57 samples: 22 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE325486_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1440334 and SRA study SRP681681. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 51 samples.
How we read this: 22 replicated groups read from 57 sample titles; they account for 51 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9568116 WT_Vehicle_1_1 WT_Vehicle_1
- GSM9568117 WT_Vehicle_1_2 WT_Vehicle_1
- GSM9568118 WT_Vehicle_2_1 WT_Vehicle_2
- GSM9568119 WT_Vehicle_2_2 WT_Vehicle_2
- GSM9568120 WT_Vehicle_3_1 WT_Vehicle_3
- GSM9568121 WT_Vehicle_3_2 WT_Vehicle_3
- GSM9568122 WT_PalboR_1_1 WT_PalboR_1
- GSM9568123 WT_PalboR_1_2 WT_PalboR_1
- GSM9568124 WT_PalboR_2_1 WT_PalboR_2
- GSM9568125 WT_PalboR_2_3 WT_PalboR_2
- GSM9568126 WT_PalboR_3_1 WT_PalboR_3
- GSM9568127 WT_PalboR_3_3 WT_PalboR_3
- GSM9568128 WT_AbemaR_1_1 WT_AbemaR_1
- GSM9568129 WT_AbemaR_1_3 WT_AbemaR_1
- GSM9568130 WT_AbemaR_2_1 WT_AbemaR_2
- GSM9568131 WT_AbemaR_2_3 WT_AbemaR_2
- GSM9568132 WT_AbemaR_3_1 WT_AbemaR_3
- GSM9568133 WT_AbemaR_3_3 WT_AbemaR_3
- GSM9568134 Mut_Vehicle_1_1 Mut_Vehicle_1
- GSM9568135 Mut_Vehicle_1_2 Mut_Vehicle_1
- GSM9568136 Mut_Vehicle_2_1 Mut_Vehicle_2
- GSM9568137 Mut_Vehicle_2_2 Mut_Vehicle_2
- GSM9568138 Mut_Vehicle_3_1 Mut_Vehicle_3
- GSM9568139 Mut_Vehicle_3_2 Mut_Vehicle_3
- GSM9568140 Mut_PalboR_1_1 Mut_PalboR_1
- GSM9568141 Mut_PalboR_1_2 Mut_PalboR_1
- GSM9568142 Mut_PalboR_3_1 Mut_PalboR_3
- GSM9568143 Mut_PalboR_3_3 Mut_PalboR_3
- GSM9568144 Mut_AbemaR_1_2 Mut_AbemaR_1
- GSM9568145 Mut_AbemaR_1_3 Mut_AbemaR_1
- GSM9568146 Mut_AbemaR_2_2 Mut_AbemaR_2
- GSM9568147 Mut_AbemaR_2_3 Mut_AbemaR_2
- GSM9568148 WT_Vehicle_1 WT_Vehicle
- GSM9568149 WT_Vehicle_2 WT_Vehicle
- GSM9568150 WT_Vehicle_3 WT_Vehicle
- GSM9568151 WT_PalboR_1 WT_Palbo
- GSM9568152 WT_PalboR_2 WT_Palbo
- GSM9568153 WT_PalboR_3 WT_Palbo
- GSM9568154 WT_AbemaR_1 WT_Abema
- GSM9568155 WT_AbemaR_3 WT_Abema
+ 17 more — browse all 57 samples with per-sample file links →
- GSE303100 Dissecting Resistance to CDK4/6 Inhibition in Experimental Glioma via Genome-wide CRISPR-Cas9 Screening 24 samples shares cdk4, resistance
- GSE268699 Genes expression alterations associated with resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer 18 samples shares cdk4, resistance
- GSE298567 Single-Cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines 14 samples shares cdk4, resistance
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares resistance, inhibitors
- GSE229733 Corticosteroid resistance is predetermined by early immune response dynamics at acute Graft-versus-Host disease onset 122 samples shares resistance, dynamics
- GSE330399 Molecular and Structural Basis of Pan-Resistance to BTK Inhibitors and Degraders 100 samples shares resistance, inhibitors
- GSE247691 Cellular adaptation to cancer therapy along a resistance continuum 93 samples shares resistance, cellular
- GSE235863 T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma 69 samples shares resistance, cellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.